Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 33, Issue 10, 2018, Pages 1787-1794

  Chan, Wah Kheong ^a   Nik Mustapha, Nik Raihan ^a   Mahadeva, Sanjiv ^a   Wong, Vincent Wai Sun ^b   Cheng, Jenny Yeuk Ki ^b   Wong, Grace Lai Hung ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CAP; controlled attenuation parameter; fibroscan; M probe; steatosis; XL probe

Indexed keywords

ADULT; ARTICLE; CHRONIC LIVER DISEASE; COMPARATIVE STUDY; CONTROLLED ATTENUATION PARAMETER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FATTY LIVER; FEMALE; HUMAN; LIVER BIOPSY; LIVER EXAMINATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; PARAMETERS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TRANSIENT ELASTOGRAPHY; ELASTICITY; ELASTOGRAPHY; FIBROSIS; LIVER; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ADULT; ELASTICITY; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; FIBROSIS; HUMANS; LIVER; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 85046442473     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.14150     Document Type: Article

References (16)

1. Friedrich-Rust M, Ong MF, Martens S et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960–974 e8
2. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2017
3. Liver EAftSot, Diabetes EAftSo. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes. Facts 2016; 9: 65–90
4. Wong VWS, Chan WK, Chitturi S et al. The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 1: definition, risk factors and assessment. J. Gastroenterol. Hepatol. 2017
5. De Franchis R. Expanding consensus in portal hypertension. J. Hepatol. 2015; 63: 743–752
6. Sasso M, Beaugrand M, De Ledinghen V et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med. Biol. 2010; 36: 1825–1835
7. Chan WK, Mustapha N, Raihan N, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2014; 29: 1470–1476
8. Myers RP, Pollett A, Kirsch R et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012; 32: 902–910
9. Sasso M, Audière S, Kemgang A et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: a pilot study assessing diagnostic accuracy. Ultrasound Med. Biol. 2016; 42: 92–103
10. Chan W-K, Nik Mustapha NR, Wong GL-H, Wong VW-S, Mahadeva S. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. United European Gastroenterol. J. 2017; 5: 76–85
11. Karlas T, Petroff D, Sasso M et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 2017; 66: 1022–1030
12. Anuurad E, Shiwaku K, Nogi A et al. The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J. Occup. Health 2003; 45: 335–343
13. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. The Lancet 2005; 366: 1059–1062
14. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321
15. Boursier J, Zarski JP, de Ledinghen V et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013; 57: 1182–1191
16. de Ledinghen V, Hiriart JB, Vergniol J, Merrouche W, Bedossa P, Paradis V. Controlled attenuation parameter (CAP) with the XL probe of the Fibroscan(R): a comparative study with the M probe and liver biopsy. Dig. Dis. Sci. 2017